Document Detail

IgE, allergic diseases, and omalizumab.
MedLine Citation:
PMID:  17073688     Owner:  NLM     Status:  MEDLINE    
Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
L M DuBuske
Related Documents :
18925888 - Clinical usefulness of microarray-based ige detection in children with suspected food a...
16784018 - Oral rush desensitization with tomato: a case report.
21028948 - In vitro model for ige mediated food allergy.
16484508 - The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis.
15162748 - Distribution and abundance of syacium ovale larvae (pleuronectiformes: paralichthyidae)...
16010118 - First responders and nuclear terrorist attacks.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  12     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2006  
Date Detail:
Created Date:  2006-10-31     Completed Date:  2007-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  3929-44     Citation Subset:  IM    
Consultant in Allergy, Brigham and Women's Hospital, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / metabolism*,  therapeutic use
Binding Sites, Antibody*
Hypersensitivity / immunology*,  metabolism,  therapy*
Immunoglobulin E / metabolism*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Binding Sites, Antibody; 0/omalizumab; 37341-29-0/Immunoglobulin E

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regulation of female fertility and identification of future contraceptive targets.
Next Document:  Lipid lowering therapy in the elderly: is there a benefit?